- Home
- PAXS vs VIR Comparison
PAXS vs VIR Comparison
Compare PAXS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- VIR
- Stock Information
- Founded
- PAXS 2021
- VIR 2016
- Country
- PAXS United States
- VIR United States
- Employees
- PAXS N/A
- VIR N/A
- Industry
- PAXS Investment Managers
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- VIR Health Care
- Exchange
- PAXS Nasdaq
- VIR Nasdaq
- Market Cap
- PAXS 677.7M
- VIR 706.4M
- IPO Year
- PAXS N/A
- VIR 2019
- Fundamental
- Price
- PAXS $15.63
- VIR $5.03
- Analyst Decision
- PAXS
- VIR Strong Buy
- Analyst Count
- PAXS 0
- VIR 8
- Target Price
- PAXS N/A
- VIR $30.25
- AVG Volume (30 Days)
- PAXS 195.0K
- VIR 1.1M
- Earning Date
- PAXS 01-01-0001
- VIR 08-06-2025
- Dividend Yield
- PAXS 11.72%
- VIR N/A
- EPS Growth
- PAXS N/A
- VIR N/A
- EPS
- PAXS N/A
- VIR N/A
- Revenue
- PAXS N/A
- VIR $20,861,000.00
- Revenue This Year
- PAXS N/A
- VIR N/A
- Revenue Next Year
- PAXS N/A
- VIR $0.56
- P/E Ratio
- PAXS N/A
- VIR N/A
- Revenue Growth
- PAXS N/A
- VIR N/A
- 52 Week Low
- PAXS $12.57
- VIR $4.32
- 52 Week High
- PAXS $15.93
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- PAXS 73.65
- VIR 39.59
- Support Level
- PAXS $15.02
- VIR $5.31
- Resistance Level
- PAXS $15.11
- VIR $5.92
- Average True Range (ATR)
- PAXS 0.11
- VIR 0.26
- MACD
- PAXS 0.05
- VIR -0.07
- Stochastic Oscillator
- PAXS 98.55
- VIR 13.24
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.